AzTrials
AzTrials

Bipolar Disorder (BD)NCT06829316

Epigenetic and Neurochemical Correlates of Bipolar Disorder

An observational study of Bipolar Disorder (BD), run by Assiut University.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Aim of Study: To assess DNA methylation of the IL1-B gene in individuals with BD compared to healthy controls. To evaluate the expression of 5-hydroxytryptamine (serotonin) receptors in BD and shed more light into its role into the pathophysioogy of BD. Read more about this study

Who is it for?
Ages 18 to 45 monthsHealthy volunteers can take part
Conditions the study is for
Bipolar Disorder (BD)
How many people
108 participants
Where
No sites listed yet
Study dates
1 Mar 2025to 30 Apr 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 months
  • All sexes
  • Healthy volunteers accepted
  • Child

Study population: A comprehensive medical history and physical examination will be conducted for all participants. Diagnosis of BD will be established based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).

Who may be able to join

  • - Adults aged 18-45 with diagnosis of BD type I.
  • Informed consent.

Who cannot join

  • - Patients who have a concurrent severe illness or inflammatory disorders will be excluded. (e.g., other CNS disorders, autoimmune diseases, cancers... etc.)
  • Current substance abuse.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Sarah S Mostafa, MBBS contact

+201097944528

sarahmostafa98@aun.edu.eg

About this study

Official title: Epigenetic and Neurochemical Correlates of Bipolar Disorder: Investigating Key Biomarkers

Aim of Study:

  • To assess DNA methylation of the IL1-B gene in individuals with BD compared to healthy controls.
  • To evaluate the expression of 5-hydroxytryptamine (serotonin) receptors in BD and shed more light into its role into the pathophysioogy of BD.
  • To measure differences of glutamic acid levels between study groups.
  • To investigate correlations between these biomarkers among study groups, and their alignment with clinical presentations.
Read the detailed description

Bipolar disorder (BD) is a chronic and multifactorial psychiatric condition characterized by recurrent episodes of mania and depression, affecting approximately 2-3% of the global population. Despite extensive research, the precise pathophysiology of BD remains incompletely understood. Studies have shown that the pathophysiology of BD involves a combination of genetic, neurobiological, and environmental factors.

Classification of Bipolar Spectrum Disorders

They are generally divided into:

  • BDI: This condition is characterized by alternating manic and depressive episodes.
  • BDII: This condition is characterized by alternating depressive and hypomanic episodes.
  • Cyclothymia: This condition is characterized by the alternation of mild depressive episodes and mild hypomanic episodes.
  • BD not otherwise specified: in this condition, patients have symptoms of mania or hypomania that are too low or too brief to meet the diagnostic criteria for a syndrome.

Research on biomarkers for BD is ongoing, but no consensus has been reached on clinically diagnostic biomarkers. Recent findings also suggest that biomarkers may vary between early and late stages of BD. Neurochemical studies have shown that various neurotransmitters, such as serotonin, dopamine, glutamate (Glu) and GABA, may be involved in the pathophysiology of BD.

Epigenetics of BD: DNA Methylation of IL-1B (an Inflammatory Cytokine) Epigenetics involves hereditable reversible changes in gene function without altering the DNA sequence, such as DNA methylation, histone modification, and non-coding RNA regulation. While initially studied in normal development, epigenetic processes are now linked to various diseases including neurological and psychiatric disorders. These mechanisms reveal how gene-environment interactions contribute to the pathogenesis and comorbidity of such disorders.

DNA methylation is an epigenetic mechanism where a methyl group is added to the C5 position of cytosine, forming 5-methylcytosine. While gene expression in eukaryotes is regulated through various mechanisms, DNA methylation a common epigenetic tool used by cells to silence genes, effectively locking them in the "off" position.

IL 1B is a proinflammatory cytokine and has been implicated in the pathophysiology of BD. A meta-analysis revealed significantly higher peripheral IL-1β levels in patients with BD compared to controls, which supports inflammatory hypothesis of mood disorders.

Studies have found an inverse correlation between DNA methylation of the IL1B, IL6, and IL8 gene promoters and their corresponding mRNA levels, with this inverse correlation being most significant for IL1B.

Serotonin Receptors Serotonin (5-hydroxytryptamine, 5-HT) is a widely known monoamine neurotransmitter that regulates neural activity and various neuropsychological processes. Research on serotonin and its receptors continues to provide new biological insights with medical relevance across various organ systems. Serotonin plays a crucial role in regulating nearly all brain functions, and disruptions in the serotonergic system have been implicated in the pathogenesis of numerous psychiatric and neurological disorders.

The role of serotonin in the pathogenesis of mood disorders, particularly major (unipolar) depression, has been extensively studied, with most research indicating decreased central serotonergic function in major depressive disorder. However, the role of serotonin in the pathogenesis of BD has received comparatively less attention. The presence of manic episodes in BD suggests different or additional neurochemical abnormalities and highlights the need for studies of BD.

The serotonin 2A receptor (5-HT2A) is one of several subtypes of 5-HT receptors and has been implicated in mental disorders with complex and still poorly understood etiologies. It plays a role in cognitive processes, such as learning and memory, as well as neurogenesis.

Given the widespread distribution of this receptor in brain regions responsible for cognitive functions and social interaction, it is involved in disorders where these functions are impaired. Conditions such as schizophrenia, depression, obsessive-compulsive disorder (OCD), and attention-deficit hyperactivity disorder (ADHD) have been linked to alterations in the 5-HT2A receptor. Numerous drugs are designed to target this receptor.

Glutamate Glutamate is the primary excitatory neurotransmitter in the nervous system, with its pathways closely linked to those of other neurotransmitters. Glutamate receptors are present throughout the brain and spinal cord, in both neurons and glia. Dysfunction in glutamate signaling has significant effects in disease and injury.

Glutamate system dysfunction has been implicated in various mood disorders, with several studies highlighting reduced glutamate levels in certain brain regions of patients with major depressive disorder (MDD). In contrast, research on BD has yielded mixed results, with some studies showing altered glutamate activity while others report no significant changes.

Medical subject headings
Bipolar Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06829316
Study groupRoleWhat they receive
Group I - PatientsPatients diagnosed with BD Diagnosis of BD will be established based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
Group IIUnaffected first-degree relatives of patients with BD in group II
Group III - ControlsAge and sex matched healthy individuals without a direct family history of BD as controls

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Biomarker levels measurement

    Measurement and comparison of levels of DNA methylation of IL-1B gene, Serotonin receptor expression, and glutamic acid levels between study groups. Identifying correlations and possible ties to pathophysiology of BD.

    Measured: Within 6 months of sample collection

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Feb 2025
  2. Study start1 Mar 2025 (estimated)
  3. Primary completion30 Mar 2026 (estimated)
  4. Study completion30 Apr 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
108 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06829316
Sponsor's protocol ID
Biomarkers in BD
Status last verified
Feb 2025
First submitted
11 Feb 2025
Last updated
17 Feb 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Mahmood T, Silverstone T. Serotonin and bipolar disorder. J Affect Disord. 2001 Sep;66(1):1-11. doi: 10.1016/s0165-0327(00)00226-3.

    PubMed 11532527
  • Grezenko H, Ekhator C, Nwabugwu NU, Ganga H, Affaf M, Abdelaziz AM, Rehman A, Shehryar A, Abbasi FA, Bellegarde SB, Khaliq AS. Epigenetics in Neurological and Psychiatric Disorders: A Comprehensive Review of Current Understanding and Future Perspectives. Cureus. 2023 Aug 23;15(8):e43960. doi: 10.7759/cureus.43960. eCollection 2023 Aug.

    PubMed 37622055
  • Cherlyn SY, Woon PS, Liu JJ, Ong WY, Tsai GC, Sim K. Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance. Neurosci Biobehav Rev. 2010 May;34(6):958-77. doi: 10.1016/j.neubiorev.2010.01.002. Epub 2010 Jan 7.

    PubMed 20060416
  • Kapczinski F, Dias VV, Kauer-Sant'Anna M, Brietzke E, Vazquez GH, Vieta E, Berk M. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Nov 13;33(8):1366-71. doi: 10.1016/j.pnpbp.2009.07.027. Epub 2009 Aug 8.

    PubMed 19666076
  • Fortinguerra S, Sorrenti V, Giusti P, Zusso M, Buriani A. Pharmacogenomic Characterization in Bipolar Spectrum Disorders. Pharmaceutics. 2019 Dec 21;12(1):13. doi: 10.3390/pharmaceutics12010013.

    PubMed 31877761
  • Machado-Vieira R, Courtes AC, Zarate CA Jr, Henter ID, Manji HK. Non-canonical pathways in the pathophysiology and therapeutics of bipolar disorder. Front Neurosci. 2023 Aug 1;17:1228455. doi: 10.3389/fnins.2023.1228455. eCollection 2023.

    PubMed 37592949

Questions about this trial

What is this clinical trial studying?

An observational study of Bipolar Disorder (BD), run by Assiut University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 17 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Sarah S Mostafa, MBBS (+201097944528, sarahmostafa98@aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Biomarker levels measurement (time frame: Within 6 months of sample collection). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06829316, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in